pcn poster

Posters

Valproate Induced Hyperammonemic Encephalopathy: Diagnosis and Management

BACKGROUND:Hyperammonemia and a carnitine deficiency with concomitant encephalopathy have been reported to result from valproate administration. The reported incidence of hyperammonemia i...

03/01/2019

WILD 5 Wellness – Results of a 90-day, Self-Directed Wellness Program in Individuals With a DSM-5 Diagnosis and Receiving Psychotropic Medications

27 adults were recruited from clinical practices and online resources, all providing informed consent to participate in this 90-day study. WILD 5 Wellness Program consists of 90-day manua...

03/01/2019

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: Analysis of a 2-year, Open-label Extension Study

Objective: To obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia Methods: Adolescents (13-17 years) who completed 6 weeks of double-bli...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

03/01/2019

Efficacy and Safety of Brexpiprazole in Patients With Schizophrenia Presenting With Severe Psychotic Symptoms During an Acute Exacerbation

Background: Schizophrenia is a chronic, disabling and progressive disease, with heterogenous symptoms and disease course between individuals. Severity of symptoms has been shown to be a s...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Nicole Meade , PhD;

Lily Shi , MSc;

03/01/2019

Efficacy and Safety of Aripiprazole Once-monthly in Patients With Relatively Rapid and Non-Rapid Cycling Bipolar I Disorder

Objective: To assess the efficacy and safety of Aripiprazole Once-Monthly (AOM 400) in preventing recurrence of mood episodes in patients with rapid and non-rapid cycling Bipolar I disord...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019

Effects of Aripiprazole Once-monthly (AOM) Across Manic Symptoms in Patients with Bipolar I Disorder (BP-I)

Background: The established role of oral aripiprazole in the treatment of Bipolar I disorder (BP-I) and the potential for a long-acting injectable formulation to improve adherence and pre...

Ross Baker , PhD, MBA;

Maninder Malik , PhD;

Pedro Such , MD;

Cathy Zhao , PhD;

Jessica Madera , MD;

03/01/2019

Effect of Lurasidone on Cognition in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term effects of lurasidone on cognition in children and adolescents with bipolar depression.

Ling Deng , PhD;

Katherine Burdick , PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

03/01/2019

Effect of Lurasidone on Cognition in Adolescents With Schizophrenia: Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the short and long-term effects of lurasidone on cognitive performance in adolescents with schizophrenia.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Philip Harvey , PhD;

Josephine Cucchiaro , PhD;

Michael Tocco , PhD;

03/01/2019

Effect of Adjunctive Brexpiprazole in Patients With Major Depressive Disorder Experiencing or Not Experiencing Activating or Sedating Adverse Events: Post Hoc Analysis Of a Short-Term Study

Objective: To determine if activating or sedating adverse events (AEs) affect the efficacy of adjunctive brexpiprazole and quetiapine extended-release (XR) in major depressive disorder (M...

03/01/2019

Economic Burden of Illness Among US Veterans With Treatment-Resistant Depression

Background: Limited evidence is available regarding the economic burden associated with treatment-resistant depression (TRD) among US Veterans. Objective: To compare the economic burden o...

Tony Amos , PharmD, MSc;

Li Wang , MS, MBA, PhD, MA;

Onur Baser , PhD, ScM, BS , MS;

Carmella Benson , MSc, MS, MSHP;

Ahong Huang , BS , MS;

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products